三阴性乳腺癌精准治疗研究的新进展与未来展望

doi:10.19401/j.cnki.1007-3639.2022.08.001

中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (8): 669-679.doi: 10.19401/j.cnki.1007-3639.2022.08.001

三阴性乳腺癌精准治疗研究的新进展与未来展望

肖玉铃()(), 朱秀之, 江一舟, 邵志敏()()

复旦大学附属肿瘤医院乳腺外科/复旦大学乳腺癌研究所,复旦大学上海医学院肿瘤学系,上海 200032

收稿日期:2022-06-20 修回日期:2022-07-10 出版日期:2022-08-30 发布日期:2022-09-19
通信作者: 邵志敏 E-mail:16307130351@fudan.edu.cn;zhimingshao@fudan.edu.cn
作者简介:肖玉铃（ORCID：0000-0002-3684-0816）,复旦大学附属肿瘤医院博士研究生,E-mail: 16307130351@fudan.edu.cn。
邵志敏,主任医师,教授,首批教育部长江学者特聘教授,国家杰出青年科学基金项目获得者,复旦大学特聘教授。现任复旦大学肿瘤研究所所长、乳腺癌研究所所长,大外科主任兼乳腺外科主任,曾任中国抗癌协会乳腺癌专业委员会主任委员,中国抗癌协会靶向治疗专业委员会主任委员,中华医学会肿瘤学分会副主任委员,第八届亚洲乳腺癌协会主席,St.Gallen乳腺癌大会专家团成员。主要从事乳腺癌的临床和基础研究,建立适合中国人群的早期筛查和诊疗流程,确立三阴性乳腺癌“复旦分型”和精准治疗策略,开展临床试验改善患者预后。已在Cancer Cell、Cell Metabolism、Cell Research、Journal of Clinical Oncology、JAMA Oncology、Journal of the National Cancer Institute等重要期刊上发表论著500余篇,被引用逾8 000次,主编专著10部。多次获得国家科技进步二等奖,教育部科技进步一、二等奖,卫健委科技进步一等奖,上海市科技进步一、二、三等奖,领衔团队入选教育部创新团队。先后主持国家自然科学基金重大项目、十五攻关课题,卫生部临床重点项目等国家级及省部级项目50余项。

New research advances and future prospect in precision treatment of triple-negative breast cancer

XIAO Yuling()(), ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin()()

Department of Breast Surgery, Fudan University Shanghai Cancer Center/Fudan University Breast Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2022-06-20 Revised:2022-07-10 Published:2022-08-30 Online:2022-09-19
Contact: SHAO Zhimin E-mail:16307130351@fudan.edu.cn;zhimingshao@fudan.edu.cn

摘要/Abstract

摘要：

世界卫生组织国际癌症研究机构最新发布的数据显示,乳腺癌现已取代肺癌成为全球发病率最高的恶性肿瘤。三阴性乳腺癌（triple-negative breast cancer,TNBC）是雌激素受体（estrogen receptor,ER）、孕激素受体（progesterone receptor,PR）和人表皮生长因子受体2（human epidermal growth factor receptor 2,HER2）表达均为阴性的乳腺癌,与其他分子分型的乳腺癌相比,TNBC具有易复发转移、整体预后差等特点。TNBC对内分泌治疗及抗HER2治疗不敏感,化疗是其主要的系统治疗手段。随着基因组学、转录组学、代谢组学、蛋白组学、微生物组学的蓬勃发展及对TNBC分子分型的深入研究,针对不同靶点的靶向治疗药物和针对免疫检查点的免疫治疗药物的出现,如多聚腺苷二磷酸核糖聚合酶[poly(ADP-ribose) polymerase,PARP]抑制剂、人滋养细胞表面抗原2（trophoblast cell-surface antigen 2,TROP-2）抗体药物偶联物、pembrolizumab、atezolizumab、durvalumab等,已为TNBC的治疗提供新的手段,正在改变TNBC的临床实践。“精准治疗”“分类而治”是未来发展的方向。本文以TNBC的分子分型为基础,对其靶向治疗和免疫治疗研究的新进展进行归纳总结,以期为今后TNBC精准治疗策略提供参考。

关键词: 三阴性乳腺癌, 分子分型, 精准治疗, 靶向治疗, 免疫治疗

Abstract:

According to the latest data released by the Cancer Research Institute of the World Health Organization, breast cancer has replaced lung cancer as the malignant tumor with the highest incidence rate in the world. Triple-negative breast cancer (TNBC) is defined by a lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Compared with other types of breast cancer, TNBC bears the characteristics of high metastasis rate, strong invasiveness and poor prognosis. TNBC is not sensitive to endocrine therapy and anti-HER2 therapy, and chemotherapy is its main systemic treatment. With the vigorous development of genomics, transcriptomics, metabolomics, proteomics, microbiomics technologies and the in-depth study of TNBC molecular subtyping, targeted therapy and immunotherapy drugs, including poly(ADP-ribose) polymerase (PARP) inhibitors, trophoblast cell-surface antigen 2 (TROP-2) antibody-drug conjugate, pembrolizumab, atezolizumab, durvalumab, etc., have provided new therapeutic methods, which are changing the clinical practice and treatment pattern of TNBC. It is believed accurate therapy will become a new direction of development in the future. Based on the molecular subtypes of TNBC, here we summarized the research advances in targeted therapy and immunotherapy of TNBC, in order to provide reference for the precise treatment strategy of TNBC in the future.

Key words: Triple-negative breast cancer, Molecular subtypes, Precision therapy, Targeted therapy, Immunotherapy

中图分类号:

R737.9

肖玉铃, 朱秀之, 江一舟, 邵志敏. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679.

XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer[J]. China Oncology, 2022, 32(8): 669-679.

参考文献 83

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	JIANG Y Z, MA D, SUO C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.e5. doi: 10.1016/j.ccell.2019.02.001
[3]	CHO B, HAN Y N, LIAN M, et al. Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer[J]. JAMA Oncol, 2021, 7(7): 1016-1023. doi: 10.1001/jamaoncol.2021.1254
[4]	YIN L, DUAN J J, BIAN X W, et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22(1): 61. doi: 10.1186/s13058-020-01296-5
[5]	LEHMANN B D, BAUER J A, CHEN X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121(7): 2750-2767. doi: 10.1172/JCI45014
[6]	LEHMANN B D, JOVANOVIĆ B, CHEN X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection[J]. PLoS One, 2016, 11(6): e0157368.
[7]	BURSTEIN M D, TSIMELZON A, POAGE G M, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer[J]. Clin Cancer Res, 2015, 21(7): 1688-1698. doi: 10.1158/1078-0432.CCR-14-0432
[8]	ZHAO S, MA D, XIAO Y, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance[J]. Oncologist, 2020, 25(10): e1481-e1491.
[9]	JIANG Y Z, LIU Y, XIAO Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial[J]. Cell Res, 2021, 31(2): 178-186. doi: 10.1038/s41422-020-0375-9
[10]	CHEN L, JIANG Y Z, WU S Y, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-plus): an open-label, single-arm, phase Ⅱ trial[J]. Clin Cancer Res, 2022, 28(13): 2807-2817. doi: 10.1158/1078-0432.CCR-21-4313
[11]	WU S Y, XU Y, CHEN L, et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial[J]. Mol Cancer, 2022, 21(1): 84. doi: 10.1186/s12943-022-01536-6
[12]	NOORDERMEER S M, VAN ATTIKUM H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells[J]. Trends Cell Biol, 2019, 29(10): 820-834. doi: 10.1016/j.tcb.2019.07.008
[13]	CORTESI L, RUGO H S, JACKISCH C. An overview of PARP inhibitors for the treatment of breast cancer[J]. Target Oncol, 2021, 16(3): 255-282. doi: 10.1007/s11523-021-00796-4
[14]	ROBSON M, IM S A, SENKUS E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6): 523-533. doi: 10.1056/NEJMoa1706450
[15]	ROBSON M E, TUNG N, CONTE P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J]. Ann Oncol, 2019, 30(4): 558-566. doi: 10.1093/annonc/mdz012
[16]	TUTT A N J, GARBER J, GELBER R D, et al. VP1-2022: pre-specified event driven analysis of overall survival (OS) in the OlympiA phase Ⅲ trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer[J]. Ann Oncol, 2022, 33(5): 566-568. doi: 10.1016/j.annonc.2022.03.008
[17]	TUTT A N J, GARBER J E, KAUFMAN B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer[J]. N Engl J Med, 2021, 384(25): 2394-2405. doi: 10.1056/NEJMoa2105215
[18]	MCGUIRE K P, ARTHUR D W, MAMOUNAS E P. Updates on management of hereditary breast cancer: new data on PARP inhibitors change recommendations regarding the multidisciplinary care of breast cancer patients with BRCA mutations[J]. Ann Surg Oncol, 2022: 2022Jun18.
[19]	LITTON J K, RUGO H S, ETTL J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8): 753-763. doi: 10.1056/NEJMoa1802905
[20]	LITTON J K, BECK J T, JONES J M, et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): results of a phase 2 study[J]. J Clin Oncol, 2021, 39(15_suppl): 505. doi: 10.1016/S0959-8049(02)00743-8
[21]	KHOURY K, FELDMAN R, POHLMANN P R, et al. Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC)[J]. J Clin Oncol, 2019, 37(15_suppl): e14651.
[22]	VRANIC S, GATALICA Z. Trop-2 protein as a therapeutic target: a focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers[J]. Bosn J Basic Med Sci, 2022, 22(1): 14-21.
[23]	BARDIA A, MAYER I A, VAHDAT L T, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751. doi: 10.1056/NEJMoa1814213
[24]	WAHBY S, FASHOYIN-AJE L, OSGOOD C L, et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer[J]. Clin Cancer Res, 2021, 27(7): 1850-1854. doi: 10.1158/1078-0432.CCR-20-3119
[25]	BARDIA A, TOLANEY S M, PUNIE K, et al. Biomarker analyses in the phase Ⅲ ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(9): 1148-1156. doi: 10.1016/j.annonc.2021.06.002
[26]	BARDIA A, HURVITZ S A, TOLANEY S M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. doi: 10.1056/NEJMoa2028485
[27]	MIRICESCU D, TOTAN A, STANESCU-SPINU I I, et al. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects[J]. Int J Mol Sci, 2020, 22(1): E173.
[28]	JANKU F, YAP T A, MERIC-BERNSTAM F. Targeting the PI3K pathway in cancer: are we making headway?[J]. Nat Rev Clin Oncol, 2018, 15(5): 273-291. doi: 10.1038/nrclinonc.2018.28
[29]	AGOSTINETTO E, EIGER D, PUNIE K, et al. Emerging therapeutics for patients with triple-negative breast cancer[J]. Curr Oncol Rep, 2021, 23(5): 57. doi: 10.1007/s11912-021-01038-6
[30]	KALINSKY K, HONG F X, MCCOURT C K, et al. Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial[J]. JAMA Oncol, 2021, 7(2): 271-278. doi: 10.1001/jamaoncol.2020.6741
[31]	SCHMID P, ABRAHAM J, CHAN S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial[J]. J Clin Oncol, 2020, 38(5): 423-433.
[32]	KIM S B, DENT R, IM S A, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2017, 18(10): 1360-1372. doi: 10.1016/S1470-2045(17)30450-3
[33]	OLIVEIRA M, SAURA C, NUCIFORO P, et al. FAIRLANE, a double-blind placebo-controlled randomized phase Ⅱ trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer[J]. Ann Oncol, 2019, 30(8): 1289-1297. doi: 10.1093/annonc/mdz177
[34]	RICCARDI C, NAPOLITANO E, PLATELLA C, et al. Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics[J]. Med Res Rev, 2021, 41(1): 464-506. doi: 10.1002/med.21737
[35]	VON MINCKWITZ G, EIDTMANN H, REZAI M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer[J]. N Engl J Med, 2012, 366(4): 299-309. doi: 10.1056/NEJMoa1111065
[36]	SHEPHERD J H, BALLMAN K, POLLEY M C, et al. CALGB 40603 (alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer[J]. J Clin Oncol, 2022, 40(12): 1323-1334. doi: 10.1200/JCO.21.01506
[37]	CAMERON D, BROWN J, DENT R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial[J]. Lancet Oncol, 2013, 14(10): 933-942. doi: 10.1016/S1470-2045(13)70335-8
[38]	MILLER K D, O’NEILL A, GRADISHAR W, et al. Double-blind phase Ⅲ trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103)[J]. J Clin Oncol, 2018, 36(25): 2621-2629. doi: 10.1200/JCO.2018.79.2028
[39]	KONO M, FUJII T, LIM B, et al. Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review[J]. JAMA Oncol, 2017, 3(9): 1266-1273. doi: 10.1001/jamaoncol.2016.4975
[40]	SALVI S, BONAFÈ M, BRAVACCINI S. Androgen receptor in breast cancer: a wolf in sheep’s clothing? A lesson from prostate cancer[J]. Semin Cancer Biol, 2020, 60: 132-137. doi: 10.1016/j.semcancer.2019.04.002
[41]	GUCALP A, TOLANEY S, ISAKOFF S J, et al. Phase Ⅱ trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer[J]. Clin Cancer Res, 2013, 19(19): 5505-5512. doi: 10.1158/1078-0432.CCR-12-3327
[42]	TRAINA T A, MILLER K, YARDLEY D A, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer[J]. J Clin Oncol, 2018, 36(9): 884-890. doi: 10.1200/JCO.2016.71.3495
[43]	TARANTINO P, CARMAGNANI PESTANA R, CORTI C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies[J]. CA Cancer J Clin, 2022, 72(2): 165-182. doi: 10.3322/caac.21705
[44]	INDINI A, RIJAVEC E, GROSSI F. Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors[J]. Int J Mol Sci, 2021, 22(9): 4774. doi: 10.3390/ijms22094774
[45]	CORTÉS J, KIM S B, CHUNG W P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer[J]. N Engl J Med, 2022, 386(12): 1143-1154. doi: 10.1056/NEJMoa2115022
[46]	MODI S N, SAURA C, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J]. N Engl J Med, 2020, 382(7): 610-621. doi: 10.1056/NEJMoa1914510
[47]	TARANTINO P, HAMILTON E, TOLANEY S M, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962.
[48]	MODI S N, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. doi: 10.1056/NEJMoa2203690
[49]	MAENNLING A E, TUR M K, NIEBERT M, et al. Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials[J]. Cancers (Basel), 2019, 11(12): E1826.
[50]	SHEN M H, JIANG Y Z, WEI Y, et al. Tinagl1 suppresses triple-negative breast cancer progression and metastasis by simultaneously inhibiting integrin/FAK and EGFR signaling[J]. Cancer Cell, 2019, 35(1): 64-80.e7. doi: 10.1016/j.ccell.2018.11.016
[51]	BERNSDORF M, INGVAR C, JÖRGENSEN L, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase Ⅱ trial[J]. Breast Cancer Res Treat, 2011, 126(2): 463-470. doi: 10.1007/s10549-011-1352-2
[52]	BASELGA J, GÓMEZ P, GREIL R, et al. Randomized phase Ⅱ study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer[J]. J Clin Oncol, 2013, 31(20): 2586-2592. doi: 10.1200/JCO.2012.46.2408
[53]	CAREY L A, RUGO H S, MARCOM P K, et al. TBCRC 001: randomized phase Ⅱ study of cetuximab in combination with carboplatin in stage Ⅳ triple-negative breast cancer[J]. J Clin Oncol, 2012, 30(21): 2615-2623. doi: 10.1200/JCO.2010.34.5579
[54]	LI C J, TZENG Y T, CHIU Y H, et al. Pathogenesis and potential therapeutic targets for triple-negative breast cancer[J]. Cancers (Basel), 2021, 13(12): 2978. doi: 10.3390/cancers13122978
[55]	AGOSTINETTO E, LOSURDO A, NADER-MARTA G, et al. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer[J]. Expert Opin Investig Drugs, 2022, 31(6): 567-591. doi: 10.1080/13543784.2022.2049232
[56]	WU S Y, WANG H, SHAO Z M, et al. Triple-negative breast cancer: new treatment strategies in the era of precision medicine[J]. Sci China Life Sci, 2021, 64(3): 372-388. doi: 10.1007/s11427-020-1714-8
[57]	TARANTINO P, ANTONARELLI G, ASCIONE L, et al. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development[J]. Expert Opin Investig Drugs, 2022, 31(6): 499-513. doi: 10.1080/13543784.2021.1972968
[58]	NANDA, CHOW L Q, DEES E C, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ⅰb KEYNOTE-012 study[J]. J Clin Oncol, 2016, 34(21): 2460-2467. doi: 10.1200/JCO.2015.64.8931
[59]	ADAMS S, SCHMID P, RUGO H S, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 397-404. doi: 10.1093/annonc/mdy517
[60]	ADAMS S, LOI S, TOPPMEYER D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 405-411. doi: 10.1093/annonc/mdy518
[61]	WINER E P, LIPATOV O, IM S A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(4): 499-511. doi: 10.1016/S1470-2045(20)30754-3
[62]	CORTES J, CESCON D W, RUGO H S, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. doi: 10.1016/S0140-6736(20)32531-9
[63]	CORTÉS J, CESCON D W, RUGO H S, et al. LBA16 KEYNOTE-355: final results from a randomized, double-blind phase Ⅲ study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC[J]. Ann Oncol, 2021, 32: S1289-S1290.
[64]	HEEKE A L, TAN A R. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer[J]. Cancer Metastasis Rev, 2021, 40(2): 537-547. doi: 10.1007/s10555-021-09972-4
[65]	SCHMID P, SALGADO R, PARK Y H, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study[J]. Ann Oncol, 2020, 31(5): 569-581. doi: 10.1016/j.annonc.2020.01.072
[66]	NANDA, LIU M C, YAU C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial[J]. JAMA Oncol, 2020, 6(5): 676-684. doi: 10.1001/jamaoncol.2019.6650
[67]	SCHMID P, CORTES J, DENT R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer[J]. N Engl J Med, 2022, 386(6): 556-567. doi: 10.1056/NEJMoa2112651
[68]	SCHMID P, CORTES J, PUSZTAI L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020, 382(9): 810-821. doi: 10.1056/NEJMoa1910549
[69]	SCHMID P, RUGO H S, ADAMS S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1): 44-59. doi: 10.1016/S1470-2045(19)30689-8
[70]	EMENS L A, ADAMS S, BARRIOS C H, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis[J]. Ann Oncol, 2021, 32(8): 983-993. doi: 10.1016/j.annonc.2021.05.355
[71]	MILES D, GLIGOROV J, ANDRÉ F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase Ⅲ trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(8): 994-1004. doi: 10.1016/j.annonc.2021.05.801
[72]	MITTENDORF E A, ZHANG H, BARRIOS C H, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial[J]. Lancet, 2020, 396(10257): 1090-1100. doi: 10.1016/S0140-6736(20)31953-X
[73]	BACHELOT T, FILLERON T, BIECHE I, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase Ⅱ SAFIR02-BREAST IMMUNO trial[J]. Nat Med, 2021, 27(2): 250-255. doi: 10.1038/s41591-020-01189-2
[74]	LOIBL S, UNTCH M, BURCHARDI N, et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019, 30(8): 1279-1288. doi: 10.1093/annonc/mdz158
[75]	TIAN Y G, LI Y L, SHAO Y P, et al. Gene modification strategies for next-generation CAR-T cells against solid cancers[J]. J Hematol Oncol, 2020, 13(1): 54. doi: 10.1186/s13045-020-00890-6
[76]	CAR-T cell therapy shows early potential in TNBC[EB/OL]. 2018, https://www.onclive.com/view/initial-results-of-car-tcell-therapy-study-show-tolerability-in-vivo-expansion-in-tnbc.
[77]	CORTI C, VENETIS K, SAJJADI E, et al. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress[J]. Expert Opin Investig Drugs, 2022, 31(6): 593-605. doi: 10.1080/13543784.2022.2054326
[78]	SAXENA M, VAN DER BURG S H, MELIEF C J M, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378. doi: 10.1038/s41568-021-00346-0
[79]	ZHU S Y, YU K D. Breast cancer vaccines: disappointing or promising?[J]. Front Immunol, 2022, 13: 828386. doi: 10.3389/fimmu.2022.828386
[80]	MORSE M A, GWIN W R 3rd, MITCHELL D A. Vaccine therapies for cancer: then and now[J]. Target Oncol, 2021, 16(2): 121-152. doi: 10.1007/s11523-020-00788-w
[81]	VINAYAK S, TOLANEY S M, SCHWARTZBERG L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer[J]. JAMA Oncol, 2019, 5(8): 1132-1140. doi: 10.1001/jamaoncol.2019.1029
[82]	PUSZTAI L, YAU C, WOLF D M, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage Ⅱ/Ⅲ breast cancer: results from the adaptively randomized I-SPY2 trial[J]. Cancer Cell, 2021, 39(7): 989-998.e5. doi: 10.1016/j.ccell.2021.05.009
[83]	CHIEN A J, GLIWA A S, RAHMAPUTRI S, et al. A phase Ⅰb trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with Myc-overexpression[J]. J Clin Oncol, 2020, 38(15_suppl): 1076. doi: 10.1200/JCO.2020.38.15_suppl.1076

三阴性乳腺癌精准治疗研究的新进展与未来展望

New research advances and future prospect in precision treatment of triple-negative breast cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 83

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张羽, 刘强. 液体活检在乳腺癌精准治疗中的应用进展及展望[J]. 中国癌症杂志, 2022, 32(8): 688-697.
[2]	周文斌, 谢晖, 丁强, 王水. 在乳腺癌局部精准治疗中的新进展：联合免疫治疗未来可期[J]. 中国癌症杂志, 2022, 32(8): 698-704.
[3]	苏春霞, 周彩存. 晚期非小细胞肺癌免疫治疗现状及未来方向[J]. 中国癌症杂志, 2022, 32(6): 478-486.
[4]	虞思来, 倪建佼, 朱正飞. 免疫治疗时代不可手术局部晚期非小细胞肺癌的治疗：现状与展望[J]. 中国癌症杂志, 2022, 32(6): 487-498.
[5]	李小秋, CD30阳性淋巴瘤病理专家组. CD30在淋巴瘤中的表达及检测：现状与挑战[J]. 中国癌症杂志, 2022, 32(6): 512-518.
[6]	宿佳琦, 徐文浩, 田熙, 艾合太木江·安外尔, 瞿元元, 施国海, 张海梁, 叶定伟. 肾透明细胞癌联合免疫治疗新策略——有氧糖酵解的研究进展及展望[J]. 中国癌症杂志, 2022, 32(4): 287-297.
[7]	陈光亮, 吴方恬, 曹军宁. 非特指EBV阳性弥漫大B细胞淋巴瘤的研究进展[J]. 中国癌症杂志, 2022, 32(3): 258-267.
[8]	李语婕, 陈颢. 靶向TROP2在胰腺癌治疗中的潜力[J]. 中国癌症杂志, 2022, 32(3): 268-273.
[9]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[10]	谢梦青, 储香玲, 周　娟, 苏春霞. 小细胞肺癌免疫治疗相关生物标志物研究进展[J]. 中国癌症杂志, 2021, 31(7): 635-639.
[11]	朱　俊, 吴小华. 2020年度妇科恶性肿瘤最新研究进展及展望[J]. 中国癌症杂志, 2021, 31(4): 250-256.
[12]	郁　俐, 沈敏娜, 姜惠琴, 王蓓丽, 郭　玮 . 同源重组缺陷检测在肿瘤临床诊疗中的研究进展与展望[J]. 中国癌症杂志, 2021, 31(4): 344-349.
[13]	胡喜娥, 杨振宇, 薛景毅, 杨　平, 彭书甲, 袁利娟, 包国强 . 单细胞测序在三阴性乳腺癌新辅助化疗中的应用研究进展[J]. 中国癌症杂志, 2021, 31(3): 221-226.
[14]	郭　晔, 张陈平 . 抗EGFR单抗治疗复发/转移性头颈部鳞状细胞癌临床共识（2021年版）[J]. 中国癌症杂志, 2021, 31(12): 1220-1232.
[15]	中国抗癌协会妇科肿瘤专业委员会, 中华医学会病理学分会, 国家病理质控中心. 子宫内膜癌分子检测中国专家共识（2021年版）[J]. 中国癌症杂志, 2021, 31(11): 1126-1144.